Asymmetry Capital Management Lowers stake in Nevro Corp (NVRO)

Nevro Corp (NVRO) : Asymmetry Capital Management reduced its stake in Nevro Corp by 10.1% during the most recent quarter end. The investment management company now holds a total of 49,377 shares of Nevro Corp which is valued at $3,294,927 after selling 5,550 shares in Nevro Corp , the firm said in a disclosure report filed with the SEC on Apr 21, 2016.Nevro Corp makes up approximately 7.79% of Asymmetry Capital Management’s portfolio.

Nevro Corp closed down -0.29 points or -0.42% at $68.21 with 2,22,576 shares getting traded on Wednesday. Post opening the session at $68.51, the shares hit an intraday low of $68.13 and an intraday high of $69.4 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Other Hedge Funds, Including , Strs Ohio reduced its stake in NVRO by selling 1,600 shares or 24.87% in the most recent quarter. The Hedge Fund company now holds 4,833 shares of NVRO which is valued at $322,506. Nevro Corp makes up approx 0.02% of Strs Ohio’s portfolio. Rhenman Partners Asset Management Ab added NVRO to its portfolio by purchasing 20,000 company shares during the most recent quarter which is valued at $1,334,600. Nevro Corp makes up approx 0.24% of Rhenman Partners Asset Management Ab’s portfolio. Simplex Trading added NVRO to its portfolio by purchasing 3,126 company shares during the most recent quarter which is valued at $213,568. Nevro Corp makes up approx 0.03% of Simplex Trading’s portfolio.Hamilton Lane Advisors reduced its stake in NVRO by selling 20,000 shares or 25.17% in the most recent quarter. The Hedge Fund company now holds 59,460 shares of NVRO which is valued at $4,062,307. Nevro Corp makes up approx 1.91% of Hamilton Lane Advisors’s portfolio. Creative Planning added NVRO to its portfolio by purchasing 121 company shares during the most recent quarter which is valued at $7,232.

On the company’s financial health, Nevro Corp reported $-0.51 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Feb 29, 2016. Analyst had a consensus of $-0.56. The company had revenue of $33.12 million for the quarter, compared to analysts expectations of $32.91 million. The company’s revenue was up 240.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.59 EPS.

Nevro Corp. is a medical device company. The Company manufactures and markets active implantable medical devices for the treatment of neurological disorders initially focusing on the treatment of chronic pain. The Company developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is the only spinal cord stimulation (SCS) system that delivers its HF10 therapy. The Company’s Senza system creates electrical impulses from two hertz to 10 kilohertz including its HF10 therapy which allows for pain relief without paresthesia. HF10 therapy delivers waveforms at 10 kilohertz pulse rate with a statistically driven and clinically verified programming algorithm. Senza consists of leads a trial stimulator an implantable pulse generator (IPG) surgical tools a clinician laptop programmer a patient remote control and a mobile charger.

Leave a Reply

Nevro Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Nevro Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.